Overview

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Status:
RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

The study will evaluate the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.

Phase:

PHASE3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

ocrelizumab